SION Stock Analysis: Sionna Therapeutics, Common | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 1.986m USD | 12M Return: 114.4% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 16.0M
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 1.4 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Sionna Therapeutics, Inc. (NASDAQ: SION) is a clinical-stage biopharmaceutical company developing treatments for cystic fibrosis (CF), a genetic disease caused by mutations in the CFTR gene. The company is headquartered in Waltham, Massachusetts, was incorporated in 2019 (previously known as Sling Therapeutics, Inc.), and completed its IPO in early 2025.
Its pipeline targets multiple CFTR mechanisms and structural domains, led by galicaftor (SION-2222) and navocaftor (SION-3067), both of which have completed Phase 2 trials, alongside earlier-stage candidates SION-109, SION-2851, SION-451, and SION-719. As a clinical-stage biopharmaceutical company, Sionna has no approved products or commercial product revenue, and its business model depends on advancing candidates through clinical development, supplemented by capital markets financing and potential future partnerships or licensing arrangements common in the biotech sector.
- Galicaftor and navocaftor Phase 2 combination data readout
- Vertexs Trikafta franchise dominates cystic fibrosis market
- Cash burn and runway drive potential equity capital raise
| Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM) |
| FCF/TA: -0.24 > 0.02 and ΔFCF/TA -8.50 > 1.0 |
| NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.24 > 3% & CFO -71.8m > Net Income -85.6m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 22.60 > 1.5 & < 3 |
| Outstanding Shares: last quarter (44.9m) vs 12m ago 1.88% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.0% > 50% (prev 0.0%; Δ 0.0% > 0%) |
| Interest Coverage Ratio: -25.93 > 6 (EBIT TTM -82.4m / Interest Expense TTM 3.18m) |
| A: 0.69 (Total Current Assets 221.0m - Total Current Liabilities 9.78m) / Total Assets 305.0m |
| B: -0.93 (Retained Earnings -283.1m / Total Assets 305.0m) |
| C: -0.24 (EBIT TTM -82.4m / Avg Total Assets 337.4m) |
| D: 17.12 (Book Value of Equity 288.2m / Total Liabilities 16.8m) |
| Altman-Z'' = 17.85 = AAA |
As of July 08, 2026, the stock is trading at USD 44.93 with a total of 630,726 shares traded. Over the past week, the price has changed by +4.56%, over one month by +34.08%, over three months by +22.23% and over the past year by +114.36%.
Current recommended Stop Loss: 41.30 (which is 8.1% or 1.3 ATR below the current price).
Sionna Therapeutics, Common has received a consensus analysts rating of 5.00. Therefore, it is recommended to buy SION.
- StrongBuy: 3
- Buy: 0
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 51.6 | 14.8% |
P/B = 6.5233
Revenue TTM = 0.0 USD
EBIT TTM = -82.4m USD
EBITDA TTM = -81.1m USD
Long Term Debt = 7.05m USD (estimated: total debt 8.38m - short term 1.32m)
Short Term Debt = 1.32m USD (from shortTermDebt, last quarter)
Debt = 8.38m USD (from shortLongTermDebtTotal, last quarter) (leases 8.38m already included)
Net Debt = -207.8m USD (calculated: Debt 8.38m - CCE 216.2m)
Enterprise Value = 1.78b USD (1.99b + Debt 8.38m - CCE 216.2m)
Interest Coverage Ratio = -25.93 (Ebit TTM -82.4m / Interest Expense TTM 3.18m)
EV/FCF = -24.65x (Enterprise Value 1.78b / FCF TTM -72.1m)
FCF Yield = -4.06% (FCF TTM -72.1m / Enterprise Value 1.78b)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 553k) / Revenue TTM)
Tobins Q-Ratio = 5.83 (Enterprise Value 1.78b / Total Assets 305.0m)
Interest Expense / Debt = 37.93% (Interest Expense 3.18m / Debt 8.38m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -65.1m (EBIT -82.4m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 22.60 (Total Current Assets 221.0m / Total Current Liabilities 9.78m)
Debt / Equity = 0.03 (Debt 8.38m / totalStockholderEquity, last quarter 288.2m)
Debt / EBITDA = 2.56 (negative EBITDA) (Net Debt -207.8m / EBITDA -81.1m)
Debt / FCF = 2.88 (negative FCF - burning cash) (Net Debt -207.8m / FCF TTM -72.1m)
Total Stockholder Equity = 313.3m (last 4 quarters mean from totalStockholderEquity)
RoA = -25.36% (Net Income -85.6m / Total Assets 305.0m)
RoE = -27.31% (Net Income TTM -85.6m / Total Stockholder Equity 313.3m)
RoCE = -25.72% (EBIT -82.4m / Capital Employed (Equity 313.3m + L.T.Debt 7.05m))
RoIC = -21.95% (negative operating profit) (NOPAT -65.1m / Invested Capital 296.6m)
WACC = 11.09% (E(1.99b)/V(1.99b) * Re(11.01%) + D(8.38m)/V(1.99b) * Rd(37.93%) * (1-Tc(0.21)))
Discount Rate = 11.01% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 22.68 | Cagr: 0.80%
[DCF] Fair Price = unknown (Cash Flow -72.1m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.27 | # QB: 0
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: N/A | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.64 | Chg30d=+0.00% | Revisions=-67% | Analysts=9
EPS next Quarter (2026-09-30): EPS=-0.65 | Chg30d=+0.00% | Revisions=-62% | Analysts=9
EPS current Year (2026-12-31): EPS=-2.54 | Chg30d=+0.00% | Revisions=-73% | GrowthEPS=-35.3% | GrowthRev=+0.0%
EPS next Year (2027-12-31): EPS=-2.80 | Chg30d=+0.00% | Revisions=-67% | GrowthEPS=-10.1% | GrowthRev=+0.0%
[Analyst] Revisions Ratio: -89% (up=0, down=25)